论文部分内容阅读
目的探讨重症急性胰腺炎患者采用前列地尔联合生长抑素的临床效果。方法选取2015年4月—2016年5月收治的72例重症急性胰腺炎患者,并采用抽签的方式将其分为2组,对照组34例患者采用生长抑素治疗,观察组38例患者采用前列地尔联合生长抑素治疗。并对两组患者的腹痛缓解时间、血淀粉酶复常时间、腹部压痛缓解时间以及临床效果情况予以比较分析,以P<0.05为差异有统计学意义。结果对照组治疗后总有效率70.59%,低于观察组患者9 4.74%,两组比较差异有统计意义(χ~2=7.534,P<0.05);观察组治疗后腹痛缓解时间、血淀粉酶复常时间以及腹部压痛缓解时间明显比对照组短,两组比较差异均有统计意义(t=3.545、4.620、8.401,均P<0.05)。结论重症急性胰腺炎患者采用前列地尔联合生长抑素的临床效果显著,可使患者腹痛缓解时间、血淀粉酶复常时间以及腹部压痛缓解时间明显缩短。
Objective To investigate the clinical effect of alprostadil combined with somatostatin in patients with severe acute pancreatitis. Methods Seventy-two patients with severe acute pancreatitis who were admitted from April 2015 to May 2016 were selected and divided into two groups by random sampling. 34 patients in the control group were treated with somatostatin, and 38 patients in the observation group Alprostadil combined with somatostatin treatment. The pain relief time, blood amylase recovery time, abdominal tenderness relief time and clinical effect were compared between the two groups. P <0.05 was considered statistically significant. Results The total effective rate of the control group was 70.59%, which was lower than that of the observation group (9 4.74%). The difference between the two groups was statistically significant (χ ~ 2 = 7.534, P <0.05) The recovery time and abdominal tenderness relief time were significantly shorter than those in the control group. There was significant difference between the two groups (t = 3.545, 4.620, 8.401, all P <0.05). Conclusion The clinical effect of combined alprostadil and somatostatin in patients with severe acute pancreatitis is significant, which can significantly reduce the pain relief time, blood amylase recovery time and abdominal tenderness relief time.